"MDCE leadership engages directly with cutting-edge innovators at CES 2026 as MDCE advances its AI wellness application portfolio." ...
TYBR Health has announced the first US clinical use of the collagen-based tissue protector, B3 GEL System, aimed at ...
Zai Lab has received approval from China’s NMPA for the sNDA for Augtyro to treat adult patients with solid tumours ...
Clinical Trials Arena on MSN
Zenas’ stock drops 51% despite lead asset’s Phase III rare disease win
While obexelimab failed to best Uplizna in terms of efficacy, Zenas will still file for the drug’s approval in IgG4-RD.
Patients reported clinically meaningful improvements in quality of life and itch. Credit: Hriana / Shutterstock.com. Alumis has announced positive top line data from its Phase III ONWARD1 and ONWARD2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback